Your browser doesn't support javascript.
loading
Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency.
Canny, Marella D; Moatti, Nathalie; Wan, Leo C K; Fradet-Turcotte, Amélie; Krasner, Danielle; Mateos-Gomez, Pedro A; Zimmermann, Michal; Orthwein, Alexandre; Juang, Yu-Chi; Zhang, Wei; Noordermeer, Sylvie M; Seclen, Eduardo; Wilson, Marcus D; Vorobyov, Andrew; Munro, Meagan; Ernst, Andreas; Ng, Timothy F; Cho, Tiffany; Cannon, Paula M; Sidhu, Sachdev S; Sicheri, Frank; Durocher, Daniel.
Afiliação
  • Canny MD; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Moatti N; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Wan LCK; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Fradet-Turcotte A; Department of Molecular Genetics, University of Toronto, Ontario, Canada.
  • Krasner D; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Mateos-Gomez PA; Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Zimmermann M; Skirball Institute of Biomolecular Medicine, Department of Cell Biology, NYU Langone Medical Center, New York, New York, USA.
  • Orthwein A; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Juang YC; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Zhang W; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Noordermeer SM; The Donnelly Centre for Cellular and Biomolecular Research, Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada.
  • Seclen E; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Wilson MD; Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Vorobyov A; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Munro M; The Donnelly Centre for Cellular and Biomolecular Research, Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada.
  • Ernst A; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Ng TF; The Donnelly Centre for Cellular and Biomolecular Research, Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada.
  • Cho T; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Cannon PM; Department of Molecular Genetics, University of Toronto, Ontario, Canada.
  • Sidhu SS; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Sicheri F; Department of Molecular Genetics, University of Toronto, Ontario, Canada.
  • Durocher D; Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Nat Biotechnol ; 36(1): 95-102, 2018 01.
Article em En | MEDLINE | ID: mdl-29176614
ABSTRACT
Programmable nucleases, such as Cas9, are used for precise genome editing by homology-dependent repair (HDR). However, HDR efficiency is constrained by competition from other double-strand break (DSB) repair pathways, including non-homologous end-joining (NHEJ). We report the discovery of a genetically encoded inhibitor of 53BP1 that increases the efficiency of HDR-dependent genome editing in human and mouse cells. 53BP1 is a key regulator of DSB repair pathway choice in eukaryotic cells and functions to favor NHEJ over HDR by suppressing end resection, which is the rate-limiting step in the initiation of HDR. We screened an existing combinatorial library of engineered ubiquitin variants for inhibitors of 53BP1. Expression of one variant, named i53 (inhibitor of 53BP1), in human and mouse cells, blocked accumulation of 53BP1 at sites of DNA damage and improved gene targeting and chromosomal gene conversion with either double-stranded DNA or single-stranded oligonucleotide donors by up to 5.6-fold. Inhibition of 53BP1 is a robust method to increase efficiency of HDR-based precise genome editing.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas CRISPR-Cas / Proteína 1 de Ligação à Proteína Supressora de Tumor p53 / Edição de Genes Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas CRISPR-Cas / Proteína 1 de Ligação à Proteína Supressora de Tumor p53 / Edição de Genes Idioma: En Ano de publicação: 2018 Tipo de documento: Article